Who, what, when and why do ideas get funded? Today we take a closer look at 11 of the most active investors in kidney care from idea to IPO— welcome to Kidney Capital. 🏙💰 https://lnkd.in/eNwEnehS
What's in the table:
• 𝐖𝐡𝐨 & 𝐖𝐡𝐞𝐧: The left-most columns in this table contain 11 of the most active investors in kidney care across the company lifecycle. This group broadly represents four investor types from idea to IPO: (a) accelerators; (b) early stage venture capital; (c) growth equity; and (d) strategic capital.
• 𝐖𝐡𝐚𝐭: There are 4 segments (colors) highlighted in this table: Care delivery (yellow), devices (purple), diagnostics (blue), and other (green). For what it’s worth, I track 9 segments across the Kidneyverse (link in comments).
• 𝐖𝐡𝐲: Investments happen because founders and investors share a unique point of view about what the future looks like. It’s as much about timing (why now?) as it is about fit (why you?). First, I’ve separated investments (solid border lines) from mergers & acquisitions (dotted lines). Second, I’ve included a crown (“👑”) for companies with an exit, either through M&A or IPO.
Insights:
1. CVS wants to deliver care to the 85% of Americans who live within 5 miles of a CVS pharmacy.
Beyond direct acquisitions (Oak Street Health, Signify Health), CVS launched their $100 million corporate venture fund in 2021 and have made a series of bets across the tech-enabled care landscape, with exciting implications for kidney care.
Examples: Strive Health, Monogram Health, Carbon Health, Waymark
--
2. Y Combinator’s healthcare and bio bets are accelerating under Subhi Sarna’s leadership
YC has been making healthcare bets since Sam Altman first took over for Paul Graham in 2014. That year, YC welcomed Ginkgo Bioworks, Inc. to its summer batch— a company that went public in 2021 and did $160 million in revenues last year. In 2017, YC welcomed its first therapeutics company. In 2021, 50 healthcare companies joined, including 20 therapeutics and 10 medical device & diagnostics startups.
YC’s most recent cohort (Winter 2023) included over 270 companies, with about 7% (20) operating in healthcare.
Examples: VenoStent, Inc., Starling (YC W22), Nephrogen, Trestle Biotherapeutics, Volumetric
--
Continue reading the post here:
💰 https://lnkd.in/eNwEnehS
Investors: CVS Health Ventures Fresenius Medical Care North America DaVita Kidney Care KidneyX Baxter International Inc. Oak HC/FT National Science Foundation (NSF) MedTech Innovator Gaingels Y Combinator
Companies: Evergreen Nephrology Interwell Health CareBridge DispatchHealth Alio CloudCath Carenostics Proton Intelligence Modulim Relavo Potrero Medical Outset Medical, Inc. Sonavex, Inc. ClosedLoop
#funding #venturecapital #healthcare #digitalhealth #medtech
